Screener
BioCryst Pharmaceuticals BCRX Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031238
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net proceeds from common stock issued under stock-based compensation plans | 19,479 | 2,390 |
| Withholding taxes paid on stock-based awards | (1,187) | (1,351) |
| Common stock issued to directors in lieu of cash retainer | 33 | 6 |
| Proceeds from term loan | 400,000 | — |
| Payment of debt issuance costs on term loan | (4,952) | — |
| Principal payments on royalty financing obligations | (476) | — |
| Principal payments on finance lease liabilities | (345) | (516) |
| Net cash provided by financing activities | 412,552 | 529 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's debt issuance proceeds?
- BioCryst Pharmaceuticals (BCRX) reported debt issuance proceeds of $400M in Q1 2026.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about BioCryst Pharmaceuticals's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude